Cell therapy Contract Development and Manufacturing Organisation (CDMO) Cellipont Bioservices announced on Wednesday that it has partnered with Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), for cGMP manufacturing of Secretome Therapeutic's lead asset STM-01.

Under this partnership, Cellipont Bioservices will provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 Master Cell Bank. STM-01, a novel nCPC product, is protected under a recently issued composition of matter patent, which also covers STM-21, Secretome's lead secretome-based therapeutic.

STM-01 is a novel cellular therapy designed to address severe cardiovascular diseases, particularly dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF).

STM-21, a secretome-based therapeutic, promotes cellular repair and reduces inflammation.